Wall Street Watches as Sanofi Sets a New Tempo
As Blueprint exits the Nasdaq stage, industry watchers are now tuning in to see how Sanofi capitalizes on its new assets. Analysts suggest the deal may spark a new wave of cross-border M&A as European pharma companies look west for innovation pipelines.
With the merger now sealed, Sanofi’s calculated risk could ignite a biotech arms race—and it’s already one step ahead.
